DURECT Corporation Reports Second Quarter 2025 Financial Results and Provides Update on Proposed Acquisition by Bausch Health
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Aug 12 2025
0mins
Source: Newsfilter
Acquisition Details: Bausch Health will acquire DURECT Corporation for $1.75 per share, totaling approximately $63 million upfront, with potential additional payments of up to $350 million based on sales milestones, expected to close in Q3 2025.
Financial Performance: DURECT reported total revenues of $447,000 and a net loss of $2.3 million for the second quarter of 2025, showing an improvement from a net loss of $3.7 million in the same period last year.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
